2-(quinolin-3-yl)hydrazinium chloride | 61621-35-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: 2-(quinolin-3-yl)hydrazinium chloride
• 英文别名: 3-hydrazinoquinoline hydrochloride；1-(quinolin-3-yl)hydrazine hydrochloride；3-Hydrazinylquinoline hydrochloride；quinolin-3-ylhydrazine;hydrochloride
• CAS: 61621-35-0
• 化学式: C₉H₉N₃*ClH
• 分子量: 195.651
• InChiKey: BOJSQUHIRFMBLP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.94
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  50.9
• 氢给体数：
  3
• 氢受体数：
  3

安全信息

• 海关编码：
  2933990090

SDS

Name:	3-Hydrazinoquinoline dihydrochloride 96% (titr.) Material Safety Data Sheet
Synonym:	None
CAS:	61621-35-0

Section 1 - Chemical Product MSDS Name:3-Hydrazinoquinoline dihydrochloride 96% (titr.) Material Safety Data Sheet
Synonym:None

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
61621-35-0	Quinoline, 3-hydrazino-, dihydrochlori	96.0	262-875-7

Hazard Symbols: None Listed.
Risk Phrases: None Listed.

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
The toxicological properties of this material have not been fully investigated.
Potential Health Effects
Eye:
May cause eye irritation.
Skin:
May cause skin irritation.
Ingestion:
May cause irritation of the digestive tract. The toxicological properties of this substance have not been fully investigated.
Inhalation:
May cause respiratory tract irritation. The toxicological properties of this substance have not been fully investigated.
Chronic:
No information found.

---

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid immediately.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes. Wash clothing before reuse.
Ingestion:
If victim is conscious and alert, give 2-4 cupfuls of milk or water.
Never give anything by mouth to an unconscious person. Get medical aid immediately.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:
Antidote: None reported.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear. During a fire, irritating and highly toxic gases may be generated by thermal decomposition or combustion.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or appropriate foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Clean up spills immediately, observing precautions in the Protective Equipment section. Sweep up or absorb material, then place into a suitable clean, dry, closed container for disposal. Avoid generating dusty conditions. Provide ventilation.

---

Section 7 - HANDLING and STORAGE
Handling:
Wash thoroughly after handling. Remove contaminated clothing and wash before reuse. Use with adequate ventilation. Minimize dust generation and accumulation. Avoid contact with eyes, skin, and clothing. Keep container tightly closed. Avoid ingestion and inhalation.
Storage:
Keep container closed when not in use. Store in a tightly closed container. Store in a cool, dry, well-ventilated area away from incompatible substances.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 61621-35-0: Personal Protective Equipment Eyes: Wear appropriate protective eyeglasses or chemical safety goggles as described by OSHA's eye and face protection regulations in 29 CFR 1910.133 or European Standard EN166.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Not available.
Color: Not available.
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: Not available.
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: N/A
Explosion Limits, upper: N/A
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C9H9N3.2HCl
Molecular Weight: 232.11

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Stable under normal temperatures and pressures.
Conditions to Avoid:
Incompatible materials, strong oxidants.
Incompatibilities with Other Materials:
Oxidizing agents.
Hazardous Decomposition Products:
Irritating and toxic fumes and gases.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 61621-35-0: VB8650000 LD50/LC50:
Not available.
Carcinogenicity:
Quinoline, 3-hydrazino-, dihydrochloride - Not listed by ACGIH, IARC, or NTP.
Other:
See actual entry in RTECS for complete information.

---

Section 12 - ECOLOGICAL INFORMATION
Other No information available.

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
Not regulated as a hazardous material.
IMO
Not regulated as a hazardous material.
RID/ADR
Not regulated as a hazardous material.

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: Not available.
Risk Phrases:
Safety Phrases:
S 24/25 Avoid contact with skin and eyes.
S 28A After contact with skin, wash immediately with
plenty of water.
S 37 Wear suitable gloves.
S 45 In case of accident or if you feel unwell, seek
medical advice immediately (show the label where
possible).
WGK (Water Danger/Protection)
CAS# 61621-35-0: No information available.
Canada
CAS# 61621-35-0 is listed on Canada's NDSL List.
CAS# 61621-35-0 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 61621-35-0 is listed on the TSCA inventory.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  2-(quinolin-3-yl)hydrazinium chloride 、 新戊酰基乙腈 以 乙醇 、 盐酸 为溶剂， 反应 16.0h， 以to yield 3-t-butyl-1-(quinolin-3-yl)-1H-pyrazol-5-amine (3.0 g, 55% yield)的产率得到3-叔丁基-1-(喹啉-3-基)-1H-吡唑-5-胺
  参考文献：
  名称：

  ENZYME MODULATORS AND TREATMENTS

  摘要：

  本发明提供了新的化合物及其使用方法，用于治疗炎症状况、过度增殖性疾病、癌症和以高血管化为特征的疾病。在优选实施例中，调节p38激酶蛋白、abl激酶蛋白、ber-abl激酶蛋白、braf激酶蛋白、VEGFR激酶蛋白或PDGFR激酶蛋白的激活状态，包括将该激酶蛋白与新的化合物接触的步骤。

  公开号：

  US20080113967A1
• 作为产物：
  描述：

  3-氨基喹啉 在 盐酸 、 sodium nitrite 、 tin(ll) chloride 作用下， 以 水 为溶剂， 反应 3.5h， 生成 2-(quinolin-3-yl)hydrazinium chloride
  参考文献：
  名称：

  [EN] UREA DERIVATIVES AS PYRUVATE KINASE ACTIVATORS
  [FR] DÉRIVÉS D'URÉE UTILISÉS EN TANT QU'ACTIVATEURS DE LA PYRUVATE KINASE

  摘要：

  本文描述的主题是针对式I的丙酮酸激酶活化化合物及其药用盐，以及制备这些化合物的方法，包括含有这些化合物的药物组合物和用于治疗与PKR和/或PKM2相关疾病的化合物的给药方法，如丙酮酸激酶缺乏症、镰刀细胞病和β-地中海贫血。

  公开号：

  WO2022031735A1

文献信息

• Antiinflammatory 1-(quinolinyl)-2-pyrazoline derivatives
  申请人：Abbott Laboratories

  公开号：US04407803A1

  公开（公告）日：1983-10-04

  Described are compounds of the formula ##STR1## wherein R.sub.2 -R.sub.8 independently of one another denote hydrogen, loweralkyl, phenyl, alkoxy, halo, hydroxy, nitro, trifluoromethyl, ##STR2## with the proviso that at least one but no more than one of the substituents R.sub.2 -R.sub.8 is ##STR3## and with the further provisos that at least four of the substituents R.sub.2 -R.sub.8 are hydrogen and R.sub.2 cannot be ##STR4## when R.sub.3 -R.sub.8 are hydrogen, and pharmaceutically acceptable salts thereof. The compounds are effective as antiinflammatory and antiasthma agents.

  描述了式子##STR1##的化合物，其中R.sub.2-R.sub.8分别独立地表示氢、低碳基、苯基、烷氧基、卤素、羟基、硝基、三氟甲基、##STR2##，但至少一个且不超过一个取代基R.sub.2-R.sub.8是##STR3##，并且进一步规定至少四个取代基R.sub.2-R.sub.8是氢，当R.sub.3-R.sub.8为氢时，R.sub.2不能是##STR4##，以及其药学上可接受的盐。这些化合物对于治疗炎症和哮喘具有有效作用。
• ENZYME MODULATORS AND TREATMENTS
  申请人：Flynn L. Daniel

  公开号：US20080113967A1

  公开（公告）日：2008-05-15

  Novel compounds and methods of using those compounds for the treatment of inflammatory conditions, hyperproliferative diseases, cancer, and diseases characterized by hyper-vascularization are provided. In a preferred embodiment, modulation of the activation state of p38 kinase protein, abl kinase protein, ber-abl kinase protein, braf kinase protein, VEGFR kinase protein, or PDGFR kinase protein comprises the step of contacting said kinase protein with the novel compounds.

  本发明提供了新的化合物及其使用方法，用于治疗炎症状况、过度增殖性疾病、癌症和以高血管化为特征的疾病。在优选实施例中，调节p38激酶蛋白、abl激酶蛋白、ber-abl激酶蛋白、braf激酶蛋白、VEGFR激酶蛋白或PDGFR激酶蛋白的激活状态，包括将该激酶蛋白与新的化合物接触的步骤。
• WO2006/71940
  申请人：——

  公开号：——

  公开（公告）日：——
• US4407803A
  申请人：——

  公开号：US4407803A

  公开（公告）日：1983-10-04
• US8163756B2
  申请人：——

  公开号：US8163756B2

  公开（公告）日：2012-04-24